204 related articles for article (PubMed ID: 24159711)
1. [Tuberous sclerosis].
Metsähonkala L; Valanne L; Anttonen AK
Duodecim; 2013; 129(17):1779-87. PubMed ID: 24159711
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex: review based on new diagnostic criteria.
Portocarrero LKL; Quental KN; Samorano LP; Oliveira ZNP; Rivitti-Machado MCDM
An Bras Dermatol; 2018 Jun; 93(3):323-331. PubMed ID: 29924239
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
[TBL] [Abstract][Full Text] [Related]
5. The pathophysiology of tuberous sclerosis complex.
Crino PB
Epilepsia; 2010 Feb; 51 Suppl 1():27-9. PubMed ID: 20331708
[No Abstract] [Full Text] [Related]
6. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin inhibitors in a patient with polycystic kidney disease-1-tuberous sclerosis-2 contiguous gene syndrome.
Anandh U; Chandrasekar G; Agarwal V
Saudi J Kidney Dis Transpl; 2018; 29(6):1475-1479. PubMed ID: 30588981
[TBL] [Abstract][Full Text] [Related]
9. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
10. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis with two unusual findings: cutaneous rhabdomyoma and chronic myelogenous leukaemia.
Bardawil T; El Jamal L; Abbas O; Kurban M
Clin Exp Dermatol; 2020 Aug; 45(6):799-801. PubMed ID: 32097503
[No Abstract] [Full Text] [Related]
12. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
[TBL] [Abstract][Full Text] [Related]
14. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
[TBL] [Abstract][Full Text] [Related]
16. Unusual radiological presentation of tuberous sclerosis complex with leptomeningeal angiomatosis associated with a hypomorphic mutation in the TSC2 gene.
Ramantani G; Niggemann P; Hahn G; Näke A; Fahsold R; Lee-Kirsch MA
J Child Neurol; 2009 Mar; 24(3):333-7. PubMed ID: 19258292
[TBL] [Abstract][Full Text] [Related]
17. Unusual clinical presentation of tuberless tuberous sclerosis complex.
Kaufmann R; Kornreich L; Goldberg-Stern H
J Child Neurol; 2009 Mar; 24(3):361-4. PubMed ID: 19258298
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
Kaufman McNamara E; Curtis AR; Fleischer AB
J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
[TBL] [Abstract][Full Text] [Related]
19. Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis.
Korf BR
Curr Opin Neurol; 1997 Apr; 10(2):131-6. PubMed ID: 9146993
[TBL] [Abstract][Full Text] [Related]
20. [Tuberous sclerosis--symptoms, diagnosis and treatment].
Farfał S; Marchelek M; Dutkiewicz G; Rózański J; Ciechanowski K; Maleszka R
Pol Merkur Lekarski; 2004 Jun; 16(96):589-91. PubMed ID: 15510904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
